Vasodilator responses and endothelin-dependent vasoconstriction in metabolically healthy obesity and the metabolic syndrome

American Journal of Physiology - Endocrinology and Metabolism

Volumn 309, Issue 9, 2015, Pages E787-E792

  Schinzari, Francesca ^a   Iantorno, Micaela ^b,c   Campia, Umberto ^d   Mores, Nadia ^a   Rovella, Valentina ^e   Tesauro, Manfredi ^e   Di Daniele, Nicola ^e   Cardillo, Carmine ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d MedStar Cardiovascular Research Network   (United States)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Endothelin 1; Endothelium; Metabolic syndrome; Obesity; Vasodilation

Indexed keywords

ACETYLCHOLINE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN; NITROPRUSSIDE SODIUM; CYCLO(TRP-ASP-PRO-VAL-LEU); CYCLOPEPTIDE; ENDOTHELIN 1;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; FOREARM BLOOD FLOW; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PLETHYSMOGRAPHY; PRIORITY JOURNAL; VASOCONSTRICTION; VASODILATATION; BLOOD FLOW; DRUG EFFECTS; FOREARM; METABOLICALLY BENIGN OBESITY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ACETYLCHOLINE; ADULT; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; FOREARM; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NITROPRUSSIDE; OBESITY, METABOLICALLY BENIGN; PEPTIDES, CYCLIC; REGIONAL BLOOD FLOW; VASOCONSTRICTION; VASODILATION;

EID: 84946101087     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00278.2015     Document Type: Article

References (33)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 37, Suppl 1: S81-S90, 2014.
2. Alberti G, Zimmet P, Shaw J, Grundy SM. IDF Metabolic Syndrome Consensus Definition. Brussels, Belgium: IDF Communications, 2006.
3. Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome-a new worldwide definition. Lancet 366: 1059-1062, 2005.
4. Andres R. Effect of obesity on total mortality. Int J Obes 4: 381-386, 1980.
5. Arnlöv J, Ingelsson E, Sundström J, Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 121: 230-236, 2010.
6. Bell JA, Kivimaki M, Hamer M. Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev 15: 504-515, 2014.
7. Bohm F, Ahlborg G, Pernow J. Endothelin-1 inhibits endotheliumdependent vasodilatation in the human forearm: reversal by ETA receptor blockade in patients with atherosclerosis. Clin Sci 102: 321-327, 2002.
8. Campia U, Matuskey LA, Panza JA. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 113: 867-875, 2006.
9. Campia U, Tesauro M, Cardillo C. Human obesity and endotheliumdependent responsiveness. Br J Pharmacol 165: 561-573, 2012.
10. Campia U, Tesauro M, Di Daniele N, Cardillo C. The vascular endothelin system in obesity and type 2 diabetes: pathophysiology and therapeutic implications. Life Sci 118: 149-155, 2014.
11. Cardillo C, Campia U, Bryant MB, Panza JA. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 106: 1783-1787, 2002.
12. Chang Y, Kim BK, Yun KE, Cho J, Zhang Y, Rampal S, Zhao D, Jung HS, Choi Y, Ahn J, Lima JA, Shin H, Guallar E, Ryu S. Metabolically-healthy obesity and coronary artery calcification. J Am Coll Cardiol 63: 2679-2686, 2014.
13. Daniele G, Guardado Mendoza R, Winnier D, Fiorentino TV, Pengou Z, Cornell J, Andreozzi F, Jenkinson C, Cersosimo E, Federici M, Tripathy D, Folli F. The inflammatory status score including IL-6, TNF-, osteopontin, fractalkine, MCP-1 and adiponectin underlies wholebody insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51: 123-131, 2014.
14. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109: III27-III32, 2004.
15. Grassi G, Seravalle G, Scopelliti F, Dell'Oro R, Fattori L, Quarti- Trevano F, Brambilla G, Schiffrin EL, Mancia G. Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity. Obesity (Silver Spring) 18: 92-98, 2010.
16. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Fernando C. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: Executive Summary. Crit Pathw Cardiol 4: 198-203, 2005.
17. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation 106: 653-658, 2002.
18. Hamer M, Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J Clin Endocrinol Metab 97: 2482-2488, 2012.
19. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med 159: 758-769, 2013.
20. Lemieux I, Pascot A, Couillard C, Lamarche B, Tchernof A, Alméras N, Bergeron J, Gaudet D, Tremblay G, Prud'homme D, Nadeau A, Després JP. Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation 102: 179-184, 2000.
21. Monroy A, Kamath S, Chavez AO, Centonze VE, Veerasamy M, Barrentine A, Wewer JJ, Coletta DK, Jenkinson C, Jhingan RM, Smokler D, Reyna S, Musi N, Khokka R, Federici M, Tripathy D, DeFronzo RA, Folli F. Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52: 2169-2181, 2009.
22. Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S, Sinopoli F, Mattioli PL. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 50: 159-165, 2001.
23. Schinzari F, Tesauro M, Rovella V, Galli A, Mores N, Porzio O, Lauro D, Cardillo C. Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients with obesity-related metabolic syndrome. Am J Physiol Endocrinol Metab 299: E947-E952, 2010.
24. Seo MH, Rhee EJ. Metabolic and cardiovascular implications of a metabolically healthy obesity phenotype. Endocrinol Metab (Seoul) 29: 427-434, 2014.
25. Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism 50: 1499-1504, 2001.
26. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97: 2601-2610, 1996.
27. Stiefel P, Vallejo-Vaz AJ, García Morillo S, Villar J. Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome. Int J Hypertens 2011: 685238, 2011.
28. Tentolouris N, Liatis S, Katsilambros N. Sympathetic system activity in obesity and metabolic syndrome. Ann NY Acad Sci 1083: 129-152, 2006.
29. Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D, Cardillo C. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 112: 2986-2992, 2005.
30. Tesauro M, Schinzari F, Rovella V, Di Daniele N, Lauro D, Mores N, Veneziani A, Cardillo C. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension 54: 995-1000, 2009.
31. Walther G, Obert P, Dutheil F, Chapier R, Lesourd B, Naughton G, Courteix D, Vinet A. Metabolic syndrome individuals with and without type 2 diabetes mellitus present generalized vascular dysfunction: crosssectional study. Arterioscler Thromb Vasc Biol 35: 1022-1029, 2015.
32. Weil BR, Westby CM, Van Guilder GP, Greiner JJ, Stauffer BL, DeSouza CA. Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol 301: H689-H695, 2011.
33. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 168: 1617-1624, 2008.